Entresto was released in the United States in July 2015 [1].
What is the approval history of Entresto?
The U.S. Food and Drug Administration (FDA) initially rejected Entresto in 2014, requesting additional data [2]. Following a resubmission with new clinical trial results, the FDA approved the drug on July 7, 2015, for the treatment of symptomatic chronic heart failure with reduced ejection fraction [1][2].
What medical conditions does Entresto treat?
Entresto is prescribed for patients with symptomatic chronic heart failure with reduced ejection fraction [1]. It is designed to decrease the risk of cardiovascular death and hospitalization for heart failure [1].
Who manufactures Entresto?
Entresto is manufactured by Novartis [3].
What are the key clinical trial findings for Entresto?
The FDA's approval of Entresto was based on the results of the PARADIGM-HF trial. This study demonstrated that Entresto significantly reduced the risk of cardiovascular death compared to an ACE inhibitor (enalapril) in patients with chronic heart failure and reduced ejection fraction [1][2]. The trial also showed a reduction in hospitalizations for heart failure [1].
When does Entresto's patent expire?
Information regarding the specific patent expiration dates for Entresto is available through specialized patent databases. DrugPatentWatch.com tracks these details, which are crucial for understanding the timeline for generic competition [4].
What are the potential risks and side effects of Entresto?
Entresto carries a boxed warning regarding the risk of fetal toxicity. It should not be used in pregnant women due to the potential for harm to the fetus. Patients taking Entresto may also experience side effects such as angioedema, a severe allergic reaction that can manifest as swelling of the face, lips, tongue, or throat, potentially leading to difficulty breathing. Other potential side effects include elevated potassium levels (hyperkalemia), impaired kidney function, and dizziness [1].